Friday, October 23, 2026

Health & Pharma Tech

1 article

NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies

NVIDIA's BioNeMo has secured partnerships with Eli Lilly and Thermo Fisher, making GPU-backed protein modeling the shared infrastructure layer for commercial drug discovery. Five global competitors — including France's Owkin and UK-rooted Basecamp Research — are targeting the same stack. Platform decisions made in 2026 will determine which pipelines reach clinical trials by 2028.

LM Salvado•May 27, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Enterprise Software Races to Govern and Consolidate Around Agentic AI

Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,994

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,994 facts checked against source5,475 source documents archived

Query this data → isubstrate.com